Haratake Naoki, Toyokawa Gouji, Tagawa Tetsuzo, Kozuma Yuka, Matsubara Taichi, Takamori Shinkichi, Akamine Takaki, Yamada Yuichi, Oda Yoshinao, Maehara Yoshihiko
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Anticancer Res. 2017 Oct;37(10):5713-5717. doi: 10.21873/anticanres.12009.
BACKGROUND/AIM: Few studies have so far described the conversion of programmed death-ligand 1 (PD-L1) after treatment. In particular, the effect of nivolumab on the PD-L1 expression has never been reported. We investigated the changes in PD-L1 expression after chemotherapy and nivolumab treatment and herein describe the detailed clinical course.
We retrospectively examined the PD-L1 expression in resected specimens and in the re-biopsy specimens of patients with non-small cell lung cancer by immunohistochemical analysis.
Four patients underwent a re-biopsy after treatment. Of those, three showed positive conversion of the PD-L1 expression. One patient underwent a re-biopsy after chemotherapy and nivolumab treatment, and the other two cases underwent a re-biopsy after chemotherapy, radiotherapy and nivolumab treatment.
These cases suggest the positive conversion of PD-L1 expression after treatments including nivolumab, suggesting that PD-L1 expression must be assessed in not only the resected specimens, but also in the re-biopsied ones.
背景/目的：目前鲜有研究描述程序性死亡配体1（PD-L1）在治疗后的变化。尤其是，纳武单抗对PD-L1表达的影响从未被报道过。我们研究了化疗和纳武单抗治疗后PD-L1表达的变化，并在此描述详细的临床过程。
我们通过免疫组织化学分析回顾性检测了非小细胞肺癌患者切除标本和再次活检标本中的PD-L1表达。
4例患者在治疗后接受了再次活检。其中，3例显示PD-L1表达阳性转化。1例患者在化疗和纳武单抗治疗后接受了再次活检，另外2例在化疗、放疗和纳武单抗治疗后接受了再次活检。
这些病例提示包括纳武单抗在内的治疗后PD-L1表达阳性转化，表明不仅要在切除标本中评估PD-L1表达，还要在再次活检标本中进行评估。
